Metabotropic glutamate receptors, which are important but difficult drug targets, interact in surprisingly varied ways with their principal regulatory proteins, according to two new studies led by Weill Cornell Medicine investigators. The findings represent a major step forward in understanding these receptors and how they can be targeted effectively to potentially treat conditions such as epilepsy, depression and anxiety disorders.